Search results
Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape· 4 days agoReal-world study data suggest there is little difference among five drug classes commonly used to...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 2 days agoCSTL provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's...
How To Get Rid Of (And Prevent) Chin Acne
Women's Health via Yahoo News· 5 days agoChin acne can be caused by your diet, hygiene practices, hormones, and plenty of other factors. Experts explain how to fight and prevent it in the first...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 3 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Cryogenic chambers and infrared capsules. This ‘fitness hotel’ is taking wellness tech to the next...
CNN.com· 2 days agoEditor’s Note: This CNN series is, or was, sponsored by the country it highlights. There are...
Little Rock Black-owned business reflects on history ahead of Juneteenth
KTHV Little Rock· 4 days agoAhead of Juneteenth, one Little Rock Black-owned business is reflecting on history. Specifically,...
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 4 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 2 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
Can High Cortisol Levels Cause Weight Gain?
MediaFeed via AOL· 4 days agoElevated cortisol levels can trigger various physical, emotional and behavioral symptoms. (These can indicate other health concerns, though, so keep that...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 4 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,